Vaccine Status Report

The sharp decline in West Africa’s Ebola cases means that researchers seeking vaccine licenses must do without the efficacy data they typically have in hand first.

From May 4 to 10, only 9 lab-confirmed cases were reported in Guinea and Sierra Leone. Thus, the phase 3 trials currently underway in West Africa may not provide even a hint of efficacy data, prompting the need to consider alternative licensing pathways, concluded experts wrapping up a 2-day WHO summit in Geneva.

Still, trials on Ebola drugs still might be able to show some efficacy and researchers may be able to evaluate the efficacy of convalescent serum treatment and gain insights into safety and immunogenicity.
CIDRAP

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top